clonoSEQ
Highly sensitive NGS-based assessment of MRD for clinical practice and drug trials
Software · OtherCompany source
Company profile
About Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Company description Adaptive Biotechnologies official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Adaptive Biotechnologies?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- autoimmune diseases
- blood cancers
- Epstein-Barr virus
- hematologic malignancies
- hepatocellular carcinoma
- infectious diseases
- multiple myeloma
- multiple sclerosis
- pancreatic ductal adenocarcinoma
- spondyloarthritis
- type 1 diabetes
Who it serves
- Clinical trial sponsors
- Clinics
- Health Systems
- Pharma
- Research institutions
Deployment & integration
Cloud Saas · Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
New data at ASCO and EHA 2026 reinforcing clonoSEQ MRD testing role. Two immune receptor licensing agreements with Pfizer announced. Earned HRC 2025 Corporate Equality Index Cornerstone Recognition. 15+ years of domain expertise milestone.
Partnerships
Recorded partners
- multiple biopharma partners for clinical trials
- Pfizer (immune receptor licensing agreements)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Connector
Streamlined portal for direct access to immune repertoire data and secure file sharing
Platform · Cloud SaaSCompany source
Immune Medicine Platform
AI-enabled platform for high-throughput T-cell and B-cell receptor sequencing at scale
Platform · OtherCompany source
TCR & BCR Deep Sequencing Services
Robust T- and B-cell sequencing assays measuring adaptive immune response breadth and depth
Service · OtherCompany source
Visualizer
Interactive tool to explore immune repertoire data and generate downloadable insights
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.American journal of hematology · Aug 1, 2026
Early Acute Leukemia Relapse After CD19-Directed CAR-T With Lineage Switch From B to T-ALL in a Pediatric Patient.Pediatric blood & cancer · Jul 25, 2026
CEI: A Clonal Expansion Identifier for T-cell receptor clones following SARS-CoV-2 vaccination.Journal of immunological methods · Jul 15, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.Blood advances · Jun 30, 2026
Minimal Residual Disease by High-Throughput Sequencing in Standard Risk-Favorable Pediatric B-Lymphoblastic Leukemia.Blood advances · Jun 24, 2026
Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.Blood advances · Jun 9, 2026
Clinical validation
Clinical-trial records
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaNCT06252675 · Sponsor · RECRUITING
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With VenetoclaxNCT04419519 · Sponsor · ACTIVE NOT RECRUITING
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentNCT07463807 · Mentioned · NOT YET RECRUITING
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell LymphomaNCT03872180 · Mentioned · ACTIVE NOT RECRUITING
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMNCT06822972 · Mentioned · RECRUITING
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaNCT04508790 · Mentioned · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
300,000+ individual repertoires sequenced
Platform scale and throughput
260+ AI-enabled models
Repertoire annotation capabilities
~100% EBV positivity detection in MS patients
Diagnostic sensitivity for EBV exposure in Multiple Sclerosis
T-cell clonal expansion correlation with patient outcomes
Immunotherapy response prediction in hepatocellular carcinoma
Memorial Sloan Kettering
Multiple myeloma treatment and MRD monitoring with clonoSEQ
Featured in Multiple Myeloma Awareness Month case study with Dr. Hamza Hashmi
CAR T therapy monitoring case study
Tracking delayed CAR T expansion driven by lentiviral CBL integration
Identified dominant CBL-integrated T-cell clone; clone contraction coincided with sustained MRD-negative remission
Hepatocellular carcinoma (uHCC) clinical trial
Checkpoint inhibitor T-cell expansion monitoring with STRIDE therapy vs durvalumab monotherapy
Increased clonal expansion with STRIDE therapy was associated with immune activation signatures and improved clinical outcomes
Multiple Sclerosis (MS) research study
EBV-specific T-cell signatures to reveal MS risk and treatment effects
~100% EBV positivity in MS patients with higher T-cell breadth than controls; EBV signature distinguishes MS from controls
Pfizer Inc.
Immune receptor licensing agreements leveraging TCR discovery capabilities and large-scale immune receptor antigen mapping data
Two immune receptor licensing agreements announced
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Chad Robins
Chief Executive Officer, Co-founder, Chairman of the Board
Harlan Robins
Chief Scientific Officer & Co-founder
Julie Rubinstein
President & Chief Operating Officer
Kyle Piskel
Chief Financial Officer
Sharon Benzeno
Chief Commercial Officer, Immune Medicine
Susan Bobulsky
Chief Commercial Officer, MRD
Francis Lo
Chief People Officer
Mary Pat Lancelotta
Senior Vice President, MRD BioPharma
06 · Company updates
Updates from Adaptive Biotechnologies
Recent articles published on Adaptive Biotechnologies's official website.
Adaptive Earns Cornerstone Recognition for LGBTQ+ Workplace Inclusion in HRC’s 2025 Corporate Equality Index
Read on Adaptive BiotechnologiesImmune Medicine in Action: How Adaptive Immunosequencing Helped Validate a Personalized Vaccine Trial in PDAC
Read on Adaptive BiotechnologiesJim’s Journey: The Power of Collaboration in Blood Cancer Care
Read on Adaptive BiotechnologiesClinically Actionable Insights: A Q&A with Dr. Luciano Costa on the Final Analysis of MASTER
Read on Adaptive BiotechnologiesHope restored: The critical role that Minimal Residual Disease can play in blood cancer patient care
Read on Adaptive Biotechnologies07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.